TTRX Stock — Turn Therapeutics Inc. Common Stock

Turn Therapeutics Inc. Common Stock (TTRX)

Updated October 16, 2026.

TTRX is a Stock. Total return is 51.0% over the past year, 36.4 points ahead of SPY at 14.6%.

Turn Therapeutics Inc. is a pharmaceuticals company developing drugs to treat diseases of the skin, nails, and eye, with delivery technology designed to penetrate the skin and nails for acute and chronic wound care applications. The company does not currently have an established distribution program. This stock may appeal to investors seeking exposure to healthcare innovation and dermatological therapeutics, though it carries the risks typical of pharmaceutical development-stage companies.

TTRX performance versus SPY

Price and return data through 2026-10-16.

Total return is 51.0% over the past year, 36.4 points ahead of SPY at 14.6%. Its deepest 1-year drawdown was 52.0%.

TTRX key facts

Asset type

Stock

Asset class

Equity

Inception date

10/08/2025

Distribution frequency

None

Last close

$10.57 (as of 2026-10-16)

Market cap

$320,986,631

Average volume

105614.0

Payout ratio

0.0%

EPS

$-0.29

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TTRX risks and drawbacks

The deepest 1-year drawdown on record here is 52.0%.

Who may consider TTRX — and who may not

It is a weaker fit for investors who need monthly cash flow (TTRX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on TTRX

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions